EN | 中文
INTRODUCTION
Many years ago, when I decided to return to China after having spent more than two decades in the U.S., I had only one thought on my mind: “The 21st century belongs to China.”

In 2005, BVCF was founded as China’s first US dollar fund that focuses on life sciences and healthcare. Since then, BVCF has embarked on an exciting adventure. BVCF chose healthcare for a simple set of rationales: China has the world’s largest population, a robust economy, rising disposable income, an inefficient healthcare system with many unmet medical needs. And more importantly: as a returnee scientist who has long worked in the field of life sciences, I consider it a great honor and mission bestowed upon me to serve my fellow countrymen.

My intuition has been proven right by the stellar track record of BVCF, which benefited greatly from the “leapfrog” development of China’s healthcare industry in the past 16 years. Our Odyssey and efforts have won us stable outsized investment returns with limited risks. And it has truly been our great privilege to rub shoulders with some of the most brilliant minds in the field and witness and support the growth of many future industry leaders.

After 16 years of exciting adventure, I’d like to extend my heartfelt gratitude towards those who have given great trust and support to us. Knowing and working with you is in itself the reason of, and reward for, our hard work.

The future presents us with a lot to look forward to. Emphasis on quality of generic drugs, greater government endorsement on local innovation and R&D improvement, a more open and dynamic capital market, etc. will boost the Chinese healthcare industry to an unprecedented height, opening up a new window of historic opportunities for all.

We look forward to another decade of success!


Zhi Yang, PhD
Chairman, Founder & Managing Partner
BVCF Managment, Ltd

FOOTPRINT
In 2005, Dr. Zhi Yang founded BioVeda China Fund (BVCF) after returning to China from the U.S. BVCF was the first US dollar fund that focused on life sciences and healthcare in China.

In the past 16 years, BVCF invested in nearly 50 companies, has US$722 million under management; and offered co-investment opportunities with a combined value of over US$1 billion. Its investments span across China and the U.S., covering a wide spectrum of highly promising subfields including healthcare services, innovative biologics, in-vitro diagnostics (molecular diagnostics), high-value medical devices and consumables, and medical big data and mobile medicine. BVCF has a complementary team of seasoned life science investors with global insight and local expertise.
They are Harvard PhDs, entrepreneurs, corporate executives, investment bankers, physicians, and the most seasoned life science investors. Well-connected and resourceful, they have provided value-added services to all portfolio companies.

BVCF is managed under international fund governance rules in its investment and operations, offering sound, transparent and professional services and safe, sustainable and outsized returns. That is why BVCF has been able to attract a large number of renowned international institutional and strategic investors, and has been tremendously valuable to entrepreneurs by offering them global insights and access to the international market.

INVESTMENT PHILOSOPHY
Life is short, that’s why we always focus our undivided attention on one area, go the extra mile on every single project and never stop in our pursuit of greater excellence.

We pursue and invest in companies with sustainable innovation and unique business models, aim to build those companies into industry leaders by leveraging our experience, resources and in some cases, by rolling up our sleeves and getting actively involved in the operations.

We believe in dreams, passion and miracles; but admire down-to-earth and persistent entrepreneurs even more. It takes a combination of all these qualities to bring about China’s own titans of the life science industries.


INVESTMENT STRATEGY
Grasp on opportunities and help place China to build global life science giants in the next few decades
● China ranks #2 in healthcare market size, but have few industry leaders in subsectors.
● Investment landmarks have shifted to innovative companies. Healthcare reform in China has driven the industry from its traditional generic industry into science and technology innovation driven industry.
● China has proposed STAR Board and Beijing Stock Exchange to offer clear exit channels for venture capital.
● Identify and invest in companies with technological differentiation and growth potential in select high-growth subsectors to build industry leaders.

Forward-looking investment strategy based on keen insight into technology and market opportunities with a seasoned investment team
● Deep-rooted resources in China with extensive local knowledge in preclinical and clinical development, regulatory knowhow, and market insights.
● Experienced all ups and downs of Chinese healthcare reform with a group of well-trained, seasoned, experienced and mature investment professionals.
● Combines science, industry and investment banking skillset together to (1) Foresight souring, invest future winners (2) Actively monitor portfolio’s operation (3) Design “smart” investment structure and facilitate value creation.

Build transformative healthcare companies ahead of market opportunities
● Built a unique ecosystem that can provide value-added services to portfolio companies, which creates synergistic chemistries between BVCF's portfolio companies.
● Help entrepreneurs make strategically critical decisions. When entrepreneurs are at a crossroads, BVCF provides our expertise to help them choose the right direction.
● Actively seek collaborative partners who will work closely with BVCF's portfolio companies to develop and achieve strategic and financial outcomes, attract talent, improve financial and operating performance, and establish responsible corporate governance.